- Home
- ENTA vs CTNM Comparison
ENTA vs CTNM Comparison
Compare ENTA & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTA
- CTNM
- Stock Information
- Founded
- ENTA 1995
- CTNM 2009
- Country
- ENTA United States
- CTNM United States
- Employees
- ENTA N/A
- CTNM N/A
- Industry
- ENTA Biotechnology: Pharmaceutical Preparations
- CTNM
- Sector
- ENTA Health Care
- CTNM
- Exchange
- ENTA Nasdaq
- CTNM Nasdaq
- Market Cap
- ENTA 112.4M
- CTNM 114.1M
- IPO Year
- ENTA 2013
- CTNM 2024
- Fundamental
- Price
- ENTA $5.93
- CTNM $3.66
- Analyst Decision
- ENTA Buy
- CTNM Strong Buy
- Analyst Count
- ENTA 4
- CTNM 4
- Target Price
- ENTA $17.25
- CTNM $22.50
- AVG Volume (30 Days)
- ENTA 119.2K
- CTNM 102.0K
- Earning Date
- ENTA 05-12-2025
- CTNM 05-14-2025
- Dividend Yield
- ENTA N/A
- CTNM N/A
- EPS Growth
- ENTA N/A
- CTNM N/A
- EPS
- ENTA N/A
- CTNM N/A
- Revenue
- ENTA $64,462,999.00
- CTNM N/A
- Revenue This Year
- ENTA N/A
- CTNM N/A
- Revenue Next Year
- ENTA N/A
- CTNM N/A
- P/E Ratio
- ENTA N/A
- CTNM N/A
- Revenue Growth
- ENTA N/A
- CTNM N/A
- 52 Week Low
- ENTA $4.09
- CTNM $3.35
- 52 Week High
- ENTA $17.24
- CTNM $22.00
- Technical
- Relative Strength Index (RSI)
- ENTA 55.39
- CTNM N/A
- Support Level
- ENTA $5.55
- CTNM N/A
- Resistance Level
- ENTA $6.23
- CTNM N/A
- Average True Range (ATR)
- ENTA 0.33
- CTNM 0.00
- MACD
- ENTA 0.05
- CTNM 0.00
- Stochastic Oscillator
- ENTA 75.31
- CTNM 0.00
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.